Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of$0.12 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.10 per share when it actually produced a loss of$0.11, delivering a surprise of -10%.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.Arbutus, which belo ...